Trikare 0.2% Lotion

Introduction

Trikare is a prescription medication that contains the active ingredient Trioxasalen. It is available under the brand name Trikare. This lotion is primarily used for the treatment of certain skin conditions, such as vitiligo and psoralen plus ultraviolet A (PUVA) photochemotherapy.

Uses

Trikare is prescribed to treat vitiligo, a skin condition characterized by patches of depigmented skin. It is also used in combination with ultraviolet A (UVA) light therapy for PUVA photochemotherapy, which is indicated for the treatment of certain skin diseases, including psoriasis.

Dosage and Administration

The dosage and administration of Trikare should be determined by a healthcare professional and may vary depending on the individual’s condition. Follow the instructions provided by your doctor or pharmacist. Generally, the lotion is applied to the affected areas of the skin and then exposed to UVA light. The frequency and duration of treatment will be determined by your healthcare provider.

Mechanism of Action

The active ingredient in Trikare, Trioxasalen, works by sensitizing the skin to UVA light. When applied to the skin and exposed to UVA light, Trioxasalen interacts with the DNA in the skin cells, which helps to restore skin pigmentation in cases of vitiligo. In PUVA photochemotherapy, Trioxasalen enhances the effectiveness of UVA light in reducing inflammation and slowing down the growth of skin cells.

Side Effects

Common side effects may include mild skin irritation, redness, itching, or a temporary darkening of the treated skin. These side effects are usually mild and resolve on their own. However, if you experience severe skin irritation, blistering, or any other unusual or persistent side effects, seek medical attention.

Drug Interactions

inform your healthcare provider about all medications you are currently taking, including prescription, over-the-counter, and herbal products. Some medications may interact with Trikare and affect its effectiveness or increase the risk of side effects. Be sure to discuss any potential drug interactions with your doctor or pharmacist.

Precautions

Before using Trikare, inform your healthcare provider about any known allergies or sensitivities to medications. Additionally, let your doctor know if you have any medical conditions, especially if you have a history of skin cancer, liver or kidney disease, or any other significant health issues. Trikare should be used with caution in pregnant or breastfeeding women, as safety data in these populations is limited.

Storage

Trikare should be stored at room temperature, away from direct sunlight and heat. Keep the bottle tightly closed when not in use, and out of the reach of children. Do not use the lotion if it has expired or if the color or consistency has changed.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the application of Trikare and the exposure to UVA light.
• Avoid excessive sun exposure and use appropriate sun protection measures, such as wearing protective clothing and applying sunscreen, while using this medication.
• If you experience any severe or persistent side effects, contact your healthcare provider for further guidance.
• Keep all follow-up appointments with your doctor to monitor your progress and adjust the treatment plan if needed.
• If you have any questions or concerns about Trikare, do not hesitate to reach out to your healthcare provider or pharmacist for clarification. They are there to support you throughout your treatment journey.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Hadjipavlou-Litina D, E Bariamis S, Militsopoulou M, Athanassopoulos CM, Papaioannou D. Trioxsalen derivatives with lipoxygenase inhibitory activity. J Enzyme Inhib Med Chem. 2009 Dec;24(6):1351-6. doi: 10.3109/14756360902932776. [Accessed 3 Jun. 2024] Available at:
• Sánchez Ruderisch H, Schwarz C, Shang J, Tebbe B. Trioxsalen in the presence of UVA is able to induce nuclear factor kappa B binding activity in HaCaT keratinocytes. Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):335-41. doi: 10.1159/000064538. [Accessed 2 Jun. 2024] Available at:
• Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, Lindelöf B, Berne B, Hannuksela M, Poikolainen K, Karvonen J. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol. 1999 Sep;141(3):497-501. doi: 10.1046/j.1365-2133.1999.03044.x. [Accessed 11 Jun. 2024] Available at:
• Skogh M. Trioxsalen vs methoxsalen in the treatment of psoriasis. Arch Dermatol. 1978 Sep;114(9):1399. [Accessed 11 Jun. 2024] Available at: